Semaglutide

Semaglutide is a synthetic analogue of the human hormone glucagon-like peptide-1 (GLP-1) and belongs to the class of GLP-1 receptor agonists ^[1]. GLP-1 is an incretin hormone released from the gut after eating that stimulates insulin, suppresses glucagon, slows stomach emptying, and promotes fullness ^[1][2]. Semaglutide is engineered to resist the rapid breakdown that inactivates natural GLP-1, giving it a half-life of about a week, which allows once-weekly dosing ^[2]. It was developed by the Danish company Novo Nordisk ^[1].

The drug was first approved for type 2 diabetes, where it improves blood sugar control, and it was later approved at a higher dose for chronic weight management in people with obesity or with overweight and weight-related conditions ^[1]. In the STEP 1 trial, adults without diabetes who received the higher-dose regimen alongside lifestyle changes lost on average about fifteen percent of their body weight, far more than with placebo ^[1]. A companion trial, STEP 4, showed that continued treatment was needed to maintain the loss, since switching to placebo led to weight regain ^[4].

Beyond glucose and weight, semaglutide reduces cardiovascular risk. In the SUSTAIN-6 trial in patients with type 2 diabetes at high cardiovascular risk, it lowered the combined rate of cardiovascular death, heart attack, and stroke compared with placebo ^[2]. The later SELECT trial extended this finding to people with overweight or obesity and established cardiovascular disease but without diabetes, where semaglutide again reduced major adverse cardiovascular events ^[3].

Semaglutide is available as a once-weekly subcutaneous injection, marketed as Ozempic for diabetes and Wegovy for weight management, and as a daily oral tablet marketed as Rybelsus ^[1]. It was first approved in the United States in 2017 for diabetes and in 2021 for weight management, and it has since become one of the most widely used and commercially successful medications in the world ^[1]. It is a prescription-only drug ^[1].

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which tend to be worst during dose escalation and often ease with time ^[1]. Less common but more serious concerns include pancreatitis, gallbladder problems, and, in animal studies, thyroid C-cell tumors, which is why it is contraindicated in people with a personal or family history of medullary thyroid carcinoma ^[1]. Because the appetite suppression and weight loss reverse after stopping, long-term use is generally required to maintain the benefit ^[4].

Semaglutide is a GLP-1 receptor agonist whose most common effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, usually dose-related. Less common but important risks include gallbladder disease, acute pancreatitis, dehydration and kidney injury from vomiting, and hypoglycemia when combined with insulin or sulfonylureas, and delayed gastric emptying can raise aspiration risk around anesthesia. It carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

Semaglutide has a remarkably clean interaction profile because it does not inhibit or induce cytochrome P450 enzymes. The major documented consideration is not a drug interaction but a food effect; semaglutide oral formulations must be taken on an empty stomach with only plain water, as food (particularly high-fat meals) impairs the absorption provided by the sodium N-[8-{2-hydroxybenzoyl}amino]caprylate (SNAC) permeation enhancer ^[23]. The interaction with other GLP-1 agonists has not been systematically studied in humans and is contraindicated on theoretical grounds. Combinations with most common medications (metformin, ACE inhibitors, statins, antidepressants) have not revealed clinically significant interactions in clinical trial data, leaving a vast unexplored space.

Checking a whole stack? Run it through interactions + stacks.

Semaglutide was developed by Novo Nordisk as part of a long-running program to extend the very short natural life of the incretin hormone GLP-1, building on the company's earlier once-daily agonist liraglutide. Chemists attached a fatty-acid side chain that binds reversibly to albumin and made substitutions that resist enzymatic breakdown, together stretching the molecule's action to roughly a week. It was first approved by the US Food and Drug Administration in 2017 as the once-weekly injection Ozempic for type 2 diabetes, followed by the oral tablet Rybelsus in 2019 and by the higher-dose Wegovy for chronic weight management in 2021. The later SELECT trial then established that it reduces the risk of major cardiovascular events in people with overweight or obesity who do not have diabetes.

Semaglutide is widely regarded as a landmark in metabolic medicine, having reshaped how obesity and type 2 diabetes are treated and drawing intense public and scientific interest. Enthusiasm rests on strong evidence: consistent double-digit weight loss, robust glucose control with a low intrinsic risk of hypoglycemia, and a documented reduction in cardiovascular events. Users and clinicians frequently note that its once-weekly dosing and, for one form, an oral option make it unusually convenient for an injectable-class drug. Honest discussion also acknowledges its limitations, including common gastrointestinal side effects such as nausea, the tendency for weight to return after stopping, and questions about long-term cost and access. On balance it is viewed as effective and well characterized while still benefiting from ongoing study of its broader effects.